ClinVar Miner

Submissions for variant NM_001009944.3(PKD1):c.-195G>A

gnomAD frequency: 0.00081  dbSNP: rs867790304
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 1
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Department of Pathology and Laboratory Medicine, Sinai Health System RCV000503375 SCV000592724 likely benign Polycystic kidney disease no assertion criteria provided clinical testing The PKD1, Promoter region, c.-195G>A variant was not identified in the literature nor was it identified in dbSNP, NHLBI GO Exome Sequencing Project, Exome Aggregation Consortium database (March 14, 2016) Clinvitae, ClinVar, GeneInsight COGR, MutDB, ADPKD Mutation Database PKD1-LOVD and PKD1-LOVD 3.0 databases. To identify conserved putative transcription factor-binding sites, a study cloned and characterized the 5'-flanking regions of the murine and canine Pkd1 genes and performed a multispecies comparison by including sequences from the human and Fugu rubripes orthologues as well as the Pkd2 promoters from mouse and human. Sequence analysis revealed a variety of conserved putative binding sites for transcription factors and no TATA-box element. Nine elements were conserved in the mammalian Pkd1 promoters: AP2, E2F, E-Box, EGRF, ETS, MINI, MZF1, SP1, and ZBP-89. Interestingly, six of these elements were also found in the mammalian Pkd2 promoters. Deletion studies with the mouse Pkd1 promoter showed that a approximately 280 bp fragment is capable of driving luciferase reporter gene expression, whereas reporter constructs containing larger fragments of the Pkd1 promoter showed a lower activity. Furthermore, mutating a potential E2F-binding site within this 280 bp fragment diminished the reporter construct activity, suggesting a role for E2F in regulating cell cycle-dependent expression of the Pkd1 gene. The data define a functional promoter region for Pkd1 and imply that E2F, EGRF, Ets, MZF1, Sp1, and ZBP-89 are potential key regulators of PKD1 and PKD2 in mammals (Lantinga-van Leeuwen 2005). In summary, based on the above information, the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a Likely Benign.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.